Jefferies downgraded Horizon Therapeutics (HZNP) to Hold from Buy after Amgen (AMGN) and Horizon announced the entry into a consent order agreement that resolves the pending FTC administrative lawsuit and “clears the path to take the final steps to close Amgen’s acquisition of Horizon.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon Therapeutics (NASDAQ:HZNP) Gains after FTC Settlement
- Amgen, Horizon enter consent order agreement with FTC to close acquisition
- AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
- Amgen, Horizon Therapeutics confirm resolution of FTC lawsuit
- Amgen to settle FTC and state challenges to Horizon Therapeutics takeover